U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06911567) titled 'A Study to Assess New Formulations of TEV-56286' on March 28.
Brief Summary: The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants.
The secondary objective is to evaluate the safety and tolerability of TEV-56286.
The planned duration for each participant is approximately 70 days which includes a 45 day screening period.
Study Start Date: March 10
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: TEV-56286 Test
Administered orally
DRUG: TEV-56286 Reference
Administered ora...